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Abstract
Achieving increased access to medicines in low- and middle-income countries is a complex issue that requires a
holistic approach. Choosing an appropriate manufacturing strategy that can ensure a sustainable supply of these
medicines is an essential component of that approach. The Chlorhexidine Working Group, a consortium of more
than 25 international organizations, donors, and manufacturers led by PATH, has been working to increase access
to 7.1 % chlorhexidine digluconate for umbilical cord care in low- and middle-income countries to reduce neonatal
mortality due to infection. The working group initially considered two strategies for manufacture of this commodity:
(1) production and global distribution by a multinational company; and (2) production and regional distribution by
locally owned companies or subsidiaries of multinational companies based in low- and middle-income countries.
Local production may be beneficial to public health and economic development in these countries, yet capability
and capacity of pharmaceutical manufacturers, regulatory and legal provisions, and market factors must be carefully
assessed and addressed to ensure that local production is the correct strategy and that it contributes to improved
access to the medicine. To date, this effort to implement a local production strategy has resulted in successful
registration of 7.1 % chlorhexidine digluconate for umbilical cord care by manufacturers in Bangladesh, Kenya,
Nepal, and Nigeria. Additionally, the product is now available in domestic and export markets.
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Background
In 1975, the World Health Assembly asked the World
Health Organization (WHO) to assist member states to
select and procure essential drugs, assuring good quality
and reasonable cost. Two years later, the first WHO
model list of essential drugs was established. Since then
WHO has been addressing the need to increase equit-
able access to and rational use of quality assured es-
sential medicines through avenues such as the WHO
Revised Drug Strategy and a prequalification program
[1]. However, in many low- and middle-income coun-
tries (LMICs), the availability of generic medicines in
the public sector is still limited; for example, availabil-
ity in the African region is only 40 % [2]. Further, even
the least expensive generic medicines available in the
African public sector are often priced higher than the
international reference prices for the same generic
medicines [2].
Severe infection is one of the top three causes of
newborn deaths worldwide, claiming approximately
15 % of all neonatal deaths each year [3]. A baby’s
newly cut umbilical cord can be an entry point for
bacteria, leading to cord infection and potentially life-
threatening sepsis. 7.1 % chlorhexidine digluconate
(delivering 4 % chlorhexidine) is a generic antiseptic
that is topically applied to the newly cut umbilical
cord in order to prevent neonatal infection. Published
data support the use of 7.1 % chlorhexidine digluco-
nate for cord cleansing as a feasible, acceptable, effica-
cious, safe, and cost-effective intervention to reduce
neonatal mortality in settings where poor hygiene and
high neonatal mortality are issues [4, 5].
In 2013, 7.1 % chlorhexidine digluconate was included in
the World Health Organization (WHO) Model List of* Correspondence: pcoffey@path.org
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Essential Medicines for Children under Specific Medicines
for Neonatal Care. In 2014, WHO recommended daily ap-
plication of 7.1 % chlorhexidine digluconate for the first
week of life to babies born at home in settings with high
neonatal mortality. The Chlorhexidine Working Group
(CWG) [6], a consortium of more than 25 international
organizations led by PATH, has been working to increase
access to this evidence-based intervention in LMICs.
Currently the WHO prequalification program evalu-
ates medicinal products used for HIV/AIDS, malaria,
tuberculosis, neglected tropical disease, and reproductive
health, as well as diagnostics, vaccines and immunization
devices. The program also provides technical assistance
to build quality assurance and manufacturing capacity at
the local country level to ensure that quality product is
available for purchase. This type of prequalification sys-
tem, however, has several limitations. The process is re-
source intensive and also puts a high burden on small
the manufacturer in terms of application costs, which
could serve to restrict product availability and cause glo-
bal shortage. Instead a harmonized, risk-based approach
could be used to maximize quality assurance. In 2011,
the joint stakeholder meeting organized by WHO and
Global Fund categorized essential medicines into high,
medium, and low risks based on therapeutic importance,
pharmacologic characteristics, complexity of manufactur-
ing procedures, and requirements associated with their
formulation or dosage form and proposed to support
quality assurance in procurement with increased rigor of
evaluations for low-risk medicines rather than WHO pre-
qualification [7].
This risk-based approach denotes 7.1 % chlorhexidine
digluconate, which is topical antiseptic, as a low-risk
generic drug and therefore its quality could be assured
with support for procurers and in-country regulatory
bodies. However, a key consideration should be given to
how to effectively and efficiently achieve this. Because its
market value and production volume are small, manu-
facturers may not be incentivized to produce 7.1 %
chlorhexidine digluconate. The lack of a centralized pro-
curement mechanism or pooled procurement system for
essential newborn drugs also does not lend itself to
motivating manufacturers to invest in production of this
type of medicine.
Therefore, determination of an appropriate manufac-
turing strategy is key to ensuring availability of high-
quality product.
Strategic selection of a potential manufacturing strategy
Achieving increased access to medicines in LMICs is a
complex issue that requires a holistic approach. Choosing
an appropriate manufacturing strategy that can ensure a
sustainable supply of these medicines is an essential com-
ponent of that approach. The CWG initially considered
two manufacturing strategies for 7.1 % chlorhexidine
digluconate: (1) Production and global distribution by a
multinational company which offers the potential benefits
that the product would likely meet high international
manufacturing and quality standards; and the company’s
regulatory expertise and distribution network could be
leveraged, which could lead to a shorter time to market
and wider coverage, and (2) Production and regional dis-
tribution by locally owned companies or subsidiaries of
multinational companies in LMICs which offers the po-
tential benefits of improved reliability of supply, foreign
import savings, development of local capability for
innovation, creation of enhanced export capacity, and
development of human capital. Local production could
also lead to cost savings and improved product quality
and regular monitoring of countries’ adherence to quality
control standards [8]. Furthermore, local manufacturers
would be able to adapt products to local cultural prefer-
ences. This approach is consistent with the African
Union Pharmaceutical Manufacturing Plan for Africa
to strengthen local ability to produce high quality, af-
fordable pharmaceuticals across the list of all essential
medicines thereby improving health outcomes and in-
creasing direct and indirect economic benefits in sub-
Saharan Africa [9].
The CWG opted for a local production strategy with
regional distribution—establishing production bases in
selected LMICs and then using them as regional hubs to
leverage local manufacturers’ regional distribution net-
works. Key reasons for the CWG’s choice include a)
the product requires neither complex manufacturing
processes nor unique production equipment; b) the
ingredients, including the active pharmaceutical ingre-
dient, are generic; and c) the primary containers for
the product are commonly available in LMICs. Add-
itionally, a local production strategy is consistent with
recent movements in LMICs toward strengthening
local pharmaceutical industries.
Linking local production and increased access to 7.1 %
chlorhexidine digluconate
Factors that need to be addressed to ensure that local
production leads to improved access to high-quality, af-
fordable medicines in LMICs include the capability and
capacity of local pharmaceutical manufacturers; quality
of local infrastructure (e.g., electrical and water supplies);
regulatory and legal provisions; economic incentives and
disincentives such as interest rates of loans, duties, and
import controls; and market size and competitive land-
scape [10]. The CWG, therefore, undertook a multi-
layered approach to address these factors.
First, the CWG assessed the feasibility of local produc-
tion by evaluating the aforementioned factors in coun-
tries that had expressed interest in implementing 7.1 %
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chlorhexidine digluconate in their newborn care pro-
grams. Based on that assessment, the CWG selected
Kenya and Nigeria as initial bases for local production in
the sub-Saharan African region. We elicited interest
from in-country manufacturers; performed good manu-
facturing practices assessments of those companies; and
identified areas for quality improvement and developed
corrective action plans, as necessary. In addition, we
conducted market research and assisted the ministries of
health and other implementing partners in developing
optimal introduction strategies to ensure increased
coverage and use of 7.1 % chlorhexidine digluconate.
The CWG provides ongoing monitoring of manufac-
turers to ascertain whether corrective action plans have
been properly implemented, and technical assistance
until they register their products with their national
regulatory authorities. It is anticipated that, over time,
national regulatory authorities will take on this role to
ensure a high quality product consistent with good
manufacturing practices.
One lesson learned during this process was that a
government’s desire for local production of medicines
is sometimes based on political reasons, even when
the country clearly lacks capacity (e.g., a pharmaceut-
ical company, good manufacturing practices compli-
ance), adequate regulatory systems to provide market
authorization of the finished product, or sufficient
market size for the product to justify its local produc-
tion. In such cases, the CWG engages in educational
dialogue with key government stakeholders. The re-
sults of the aforementioned feasibility assessments are
quite helpful for those discussions.
Another lesson learned was how to incentivize manu-
facturers to produce 7.1 % chlorhexidine digluconate.
The CWG included them as full members in the group.
This enabled manufacturers to gain name recognition,
access to key programmatic and policy stakeholders, and
potential buyers, and market intelligence which in turn
helped them to reduce cost for market entry. In
addition, manufacturers that we reached typically had a
low capacity utilization rate, and filling ample, unused
capacity with product demand which the CWG helped
generate worked as a strong incentive. Finally, manufac-
turers are increasing their recognition of corporate social
responsibility. Producing 7.1 % chlorhexidine digluco-
nate to reduce neonatal mortality appealed to their sense
of social responsibility.
Conclusion
Since 2013, the CWG is implementing a local produc-
tion strategy with regional distribution in some LMICs
in order to increase access to 7.1 % chlorhexidine diglu-
conate. Although local production has benefits for public
health and economic development of LMICs, several
factors—such as capability and capacity of pharmaceut-
ical manufacturers, regulatory and legal provisions, and
market factors—must be carefully assessed and ad-
dressed to ensure that local production is the correct
strategy and that it contributes to improved access to
the medicine. To date, this effort has resulted in success-
ful registration of 7.1 % chlorhexidine digluconate by
manufacturers in Bangladesh, Kenya, Nepal, and Nigeria.
Additionally, the product is now available in domestic
and export markets. Data are currently being collected
to explore the effect this has had on availability and neo-
natal mortality rates.
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